All manuscripts
Publications CAR T Cells NK Cells T-Cells G-Rex®500M-CS

G-Rex® bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

Published Journal Cell and Gene Therapy Insights

Share
8 pages G-Rex bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production — Cell and Gene Therapy Insights, 2024

Overview

This article details how closed-system G-Rex® bioreactors, specifically the G-Rex® 500M-CS, paired with Heracell Vios incubators, prevent contamination in cell therapy production. It confirms G-Rex® sterile fluid path integrity via microbial ingress and viral penetration testing.

What this paper found

Closed-system G-Rex® bioreactors held in Vios iDx CR CO2 incubators showed no bacterial ingress and no viral penetration, supporting contamination-controlled parallel cell therapy manufacturing. In a 14-day full-immersion bacterial challenge, all three test bioreactors showed no growth. All 32 membrane samples passed bacteriophage Phi-X174 penetration testing, with an assay titer below 1 PFU/mL. With ten filled G-Rex® 500M-CS in the chamber, temperature recovered in 5.3 minutes and CO2 in 5.0 minutes after a 60-second door opening. The CultiMaxx shelving kept temperature uniformity within ±0.3 °C, and in-chamber HEPA filtration reached ISO Class 5 in about 5 minutes. Stacked incubators could yield a projected 400 billion cells in just over 3 square feet.

Note: The cell yields cited are projections from reported per-vessel capacity; the tests described are equipment and device tests, not cell cultures.

These test results support closed-system G-Rex bioreactors in cell therapy and GMCT manufacturing processes in low-cost and lower-grade cleanrooms. — Mary Kay Bates, Dan Fick, Jürgen Schneider, Dan Welch, Josh Ludwig, Cell and Gene Therapy Insights

Study details

Authors
Mary Kay Bates, Dan Fick, Jürgen Schneider, Dan Welch, Josh Ludwig
Institution
Thermo Fisher Scientific, Waltham, MA, USA · Wilson Wolf Manufacturing LLC, St Paul, MN, USA · ScaleReady USA LLC, St Paul, MN, USA
Journal
Cell and Gene Therapy Insights
Year
2024
G-Rex® model(s)
G-Rex®500M-CS
Cell type(s)
CAR T Cells, NK Cells, T-Cells
Application area
Other
Study phase
Preclinical

How G-Rex® was used

Ten G-Rex® 500M-CS bioreactors, each filled with 5 L of water pre-heated to 37 °C, were loaded into a Vios iDx CR CO2 incubator on CultiMaxx shelving to test temperature, CO2 and humidity recovery after a 60-second opening of both doors. For the microbial ingress test, test bioreactors were filled with 5,000 mL of Nutrient Broth Media, weighted and fully immersed in 12 L of bacterial challenge solution for 14 days; all three showed no growth. In a separate test, 32 samples of G-Rex® membrane material showed no bacteriophage penetration.

Explore related

Full citation

Bates MK, Fick D, Schneider J, Welch D, Ludwig J. G-Rex bioreactors incubated in Heracell™ Vios™ CR CO2 Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production. Cell Gene Therapy Insights. 2024;10(04):593-607.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →